



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/405,920		
		Filing Date	September 24, 1999		
		First Named Inventor	Serge CARILLO et al.		
		Art Unit	1632		
		Examiner Name	A. Beckerleg		
Sheet	1	of	2	Attorney Docket Number	ST94037

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US-			
	B1	US-			
	C1	US-			
	D1	US-			
	E1	US-			
	F1	US-			
	G1	US-			
	H1	US-			
	I1	US-			
	J1	US-			
	K1	US-			
	L1	US-			
	M1	US-			
	N1	US-			
	O1	US-			
	P1	US-			
	Q1	US-			
	R1	US-			
	S1	US-			
	T1	US-			

RECEIVED

OCT 21 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	FA1	WO 00/21575	04-20-2000	Atencio		
	FA2					
	FA3					
	FA4					
	FA5					
	FA6					
	FA7					
	FA8					
	FA9					
	FA10					

Examiner Signature	<i>[Signature]</i>	Date Considered	1/28/03
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/405,920
		Filing Date	September 24, 1999
		First Named Inventor	Serge CARILLO et al.
		Group Art Unit	1632
		Examiner Name	A. Beckerleg
		Attorney Docket Number	ST94037A
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Wagenknecht et al., "Proteasome Inhibitors Induce p53/p21-Independent Apoptosis in Human Glioma Cells", Cell Physiol Biochem 1999; 9:117-125	
		An et al., "Protease inhibitor-induced apoptosis: accumulation of wt p53, p51 WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibitor", Leukemia (2000) 14; 1276-1283	
		Kubbutat et al., "Proteolytic Cleavage of Human p53 by Calpain: a Potential Regulator of Protein Stability", Molecular and Cellular Biology, Jan. 1997; pp. 460-468	
		Kubbutat and Vousden, "Keeping an old friend under control: regulation of p53 stability", Molecular Medicine Today, June 1998; pp. 250-256	
		Atencio et al., "Caspain Inhibitor 1 Activates p53-dependent Apoptosis in Tumor Cell Lines", Cell Growth & Differentiation, May 2000; Vol. 11, 247-253	
		Pariat, et al., "Proteolysis by Calpains: a Possible Contribution to Degradation of p53", Molecular and Cellular Biology, May 1997; Vol. 17 No. 5, pp. 2806-2815	
		Carafoli, et al., "Breakthroughs and Views Calpain: A Protease in Search of a Function?", Biochemical and Biophysical Research Communications 247, 193-203 (1998)	

RECEIVED
OCT 24 2002
TECH CENTER 1600/2900

Examiner Signature		Date Considered	1/23/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.